<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nongastric marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>) is a relatively uncommon indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>From 1990 to 2005, a total of 247 patients with histologically confirmed NG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>Ann Arbor stage I/II disease was present in 78% (167 out of 215) </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred eighty-six patients out of two hundred eight were categorized into the low/low-intermediate risk group (89%) according to International Prognostic Index (IPI) </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty percent (172/215) were in low risk group according to Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index (FLIPI) </plain></SENT>
<SENT sid="5" pm="."><plain>Complete and partial remissions (CR and PR) were achieved in 140 (92.7%) and 8 (5.3%) of the 151 stage I/II patients </plain></SENT>
<SENT sid="6" pm="."><plain>Especially, radiation containing treatment achieved 96% CR rate (108 out of 113) </plain></SENT>
<SENT sid="7" pm="."><plain>In 38 patients with stage III/IV, CR and PR were achieved in 17 (44.7%) and 11 (26.3%), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The estimated five-year overall survival (OS) and progression-free survival (PFS) were 93.8% and 70.1%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Although <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-containing regimen could achieve higher CR rate, it did not improve PFS </plain></SENT>
<SENT sid="10" pm="."><plain>Stage III/IV, low <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, poor performance status, high/high-intermediate IPI, poor risk FLIPI, and nodal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> were poor prognostic factors for PFS </plain></SENT>
<SENT sid="11" pm="."><plain>NG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> is an indolent disease </plain></SENT>
<SENT sid="12" pm="."><plain>FLIPI has strong power to predict the prognosis of NG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> </plain></SENT>
</text></document>